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Abstract 
We report formation of polymorphs and new eutectics and co-crystals of curcumin, a 
sparingly water soluble active component in turmeric, with structurally similar cinnamic acid. 
The curcumin polymorphs were formed using liquid anti-solvent precipitation, where acetone 
acted as a solvent while water was used as the anti-solvent. The metastable Form 2 of 30 
curcumin was successfully prepared in varied morphology over a wide range of solvent to 
anti-solvent ratio and under acidic pH conditions.  
We also report formation of new eutectics and co-crystals of curcumin with cinnamic 
acid acting as a co-former.  The binary phase diagrams were studied using differential 
scanning calorimetry (DSC) that predict formation of the  eutectics at the curcumin mole 35 
fraction of 0.15 and 0.33, while a co-crystal is formed at 0.3 mole fraction of curcumin in the 
curcumin-cinnamic acid mixture. The formation of the co-crystal was supported with X-ray 
powder diffraction (p-XRD), the enthalpy of fusion values and Fourier Transform Infrared 
(FTIR) Spectroscopy and Scanning Electron Microscopy (SEM). The hydrogen bond 
interaction between curcumin and cinnamic acid is predicted from FTIR spectra, individually 40 
optimized curcumin and cinnamic acid structures by quantum mechanical calculations using 
Gaussion-09 and their respective unit cell packing structures. 
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Introduction 
Curcumin, one of the major naturally active components of turmeric, shows a wide 
spectrum of biological and pharmacological activities which makes it a potential drug for 
treatment of various diseases. Despite its efficacy and pharmacological safety, the main 
limitation of curcumin-based formulations is poor water solubility of curcumin because of its 55 
poly-phenolic hydrophobic structure. Poor absorption and rapid metabolism adversely affect   
bioavailability of curcumin from the formulations.
1-2
  
In order to increase its solubility, stability and pharmacological activity for optimum 
therapeutic effect, chemically modified curcumin derivatives as well as improved 
formulations and delivery systems are being studied.
3-7
 Multiple approaches, including 60 
development of its analogues, liposomal and nanoparticle formulations, and crosslinking with 
other drugs, etc., are being developed to overcome these limitations.
8-12 
 
Formation of polymorphs, eutectics and co-crystals are other possible ways to 
overcome poor bioavailability of curcumin. Polymorphs of various drugs like carbamazepine, 
sulfamerazine, mefenamic acid, methylprednisolone, D-mannitol, etc., have been reviewed 65 
for decades and are well documented in literature.
13-21
 Curcumin reportedly shows three 
polymorphs of which the Form 1, the most common crystalline form of curcumin, is most 
stable. Amongst, the other two polymorphs of curcumin, Form 2 shows higher dissolution 
rate as compared to Form 1. The Form 3 of the curcumin, has been reported to be unstable 
and thus is difficult to reproduce.
22 
Liquid anti-solvent precipitation of curcumin to form 70 
different polymorphs with assistance of ultrasound and/or in the presence of different 
stabilizers has been reported recently.
23, 24 
In recent years, studies of various co-crystals have become important, to provide a 
number of crystalline states of an Active Pharmaceutical Ingredient (API), in which physical 
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and chemical properties such as solubility, stability and bioavailability, are enhanced without 75 
affecting the chemical composition of APIs.
25 
All the major co-crystals of the interest from 
pharmaceutical point of view have been reviewed recently,.
26
 The formation of co-crystals 
seems to be an emerging field for enhancing specific properties of the APIs.
27 
Reports of co-crystal formation of curcumin or its eutectics with poly-
hydroxybenzenes, aromatic acids, amides, amines and amine oxides, have been listed well in 80 
the literature, with improved solubility and enhanced rates of solubilization of curcumin 
along with the coformers.
28-30
 The co-crystals of curcumin with resorcinol and pyrogallol 
show higher solubilization rates, 5 and 12 times, respectively, as compared to pure curcumin, 
in water.
28
 The intermolecular hydrogen bonding with the hydroxyl group of hydroxyquinol 
leads to formation of two different types of cocrystals with curcumin; one in 1:2 ratio 85 
showing a better dissolution rate as compared to another cocrystal formed in 1:1 ratio. 
Stronger intramolecular H-bonding interaction in salicylic acid, however, results in formation 
of an eutectic of the acid with curcumin. 
29
 Recently, Katherine et. al.
 30
 have reported 
formation of curcumin-dextrose co-crystals by solution crystallization where the dextrose 
concentration and temperature of the process affected the co-crystal formation. The 90 
curcumin-dextrose co-crystals also showed a remarkable solubility increase than curcumin 
alone, i.e. upto 2.5% in water.
 
The solubility of curcumin in pure water is otherwise 
extremely low. Cocrystals of curcumin with Ibuprufen, naproxen, benzimidazole and lysine 
have been also reported.
31, 32
 Although, most coformers forming co-crystals with curcumin 
have aromatic structures, the coformers such as dextrose, piperazine and lysine defy the logic 95 
of necessity of existence of π interactions to form the cocrystals.30-32 Apparently, the presence 
of either -OH or NH2 or a carbonyl group, is sufficient to form the cocrystals. The presence 
of π interactions could be an additional advantage. 
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Polymorphic Form 2 of curcumin has been proven to be more easily soluble than the 
commercially available Form 1 of curcumin.
22
 This paper reports a simpler method for  100 
formation of polymorphs of curcumin; particularly Form 2, using an anti-solvent 
precipitation method, over a range of solvent-to-anti-solvent ratio and under varying pH 
conditions.  
We also report new eutectics and co-crystal of curcumin with cinnamic acid using a 
solid state grinding method. Cinnamic acid was chosen as a co-former for the co-crystal 105 
formation with curcumin as it is a natural analogue of curcumin because of the structural 
similarity. The encircled portion in the curcumin structure is similar to the structure of 
cinnamic acid. 
 
Cinnamic acid is similar to one half of the basic curcumin skeleton structure.
12
 The 110 
types of hydrogen bonds and molecular aggregate formation within co-crystal components 
can be predicted by a few general rules.
33-35 
The acidic hydrogen in cinnamic acid helps in H-
bonding with the phenolic –OH groups of curcumin that act as hydrogen bond acceptors. 
Cinnamic acid and its derivatives are also known to possess hepatoprotective, antioxidant and 
anti-cancer activities and would add value in therapeutic applications of curcumin in the API 115 
formulations.
36-38
  The binary phase diagram for curcumin and cinnamic acid system is 
further studied in detail to define the eutectic and the co-crystal regions.  
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Experimental section 
Materials  
Curcumin (>95 %) was procured from Sigma-Aldrich. Acetone (99.5 % pure), 120 
methanol (> 99.8 %), ethanol (> 99.8 %), acetonitrile (> 99.93 %), hydrochloric acid (37%) 
and potassium chloride (> 99 %) were also purchased from Sigma-Aldrich. Cinnamic acid 
(99.5 % pure) was purchased from Molychem, Mumbai. De-ionised water from Milli Q 
system was used for all the experiments.  
Methods 125 
Polymorphic studies of Curcumin by anti-solvent method  
 A stock solution of curcumin was first prepared in acetone (500 mg dm
-3
). In a typical 
experiment, a known volume of the curcumin solution in acetone was added to a known 
volume of water, an anti-solvent. For example, for preparing a solution mixture of 1:10 
solvent-to-anti-solvent ratio, 1 cm
3
 of the stock solution of curcumin in acetone was added to 130 
a beaker containing 10 cm
3
 of water under stirred conditions, both maintained at a constant 
temperature of 30ºC in a water bath. Immediate precipitation was seen on the addition of the 
curcumin solution. The suspension was vacuum filtered (using Whatman filter paper, grade 
50) after 2 min to recover the precipitated curcumin. The solid was kept in open for air drying 
at room temperature for several hours, till it formed a dry and free flowing powder. The final 135 
powder was used for analysis by different techniques. The same procedure was repeated for 
2:10, 3:10, 4:10 and 5:10, solvent-to-anti-solvent ratios in exactly the same manner.  
In another set of experiments, for varying the anti-solvent to solvent ratio, varying 
volumes of water (4, 6 and 8 cm
3
) were poured into beaker containing a fixed amount (1 cm
3
) 
of the stock solution of curcumin in acetone to form 1:4, 1:6 and 1:8 solvent-to-anti-solvent 140 
ratios in the final mixture.  
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Experiments were conducted by varying the pH of the anti-solvent from 1.5 to 5 using 
a buffer system of hydrochloric acid and potassium chloride with ionic strength of 0.1 M- 
0.15 M.  
All the solid samples were analysed by differential scanning calorimetry (DSC) using 145 
a Simultaneous Thermal Analyser (STA) Perkin Elmer 6000 apparatus. X-ray powder 
diffraction (p-XRD) pattern of the samples was analysed using a Bruker D8 diffractometer 
(X-ray wavelength – 0.154 nm, source – Cu, voltage – 40 kV and filament emission – 40 
mA). All samples were scanned for 2θ values from 2 to 30° with 0.01° step width. A 
Scanning Electron Microscopy (SEM) using JEOL, (JSM-638OLA, Japan) Electron 150 
Scanning Microscope, was used for checking the morphology of the solid samples. All the 
above experiments were performed twice.  
Eutectics and Co-crystals of Curcumin with Cinnamic Acid 
The binary phase diagram studies were conducted using differential thermal analysis 
for determining the molar ratio of curcumin to cinnamic acid at which the eutectics or co-155 
crystals are formed. This method is a high-performance screening system, particularly for 
APIs with low solubility and/or propensity to form solvates.
42
  
Ten samples of physical mixtures of curcumin and cinnamic acid covering the entire 
composition range were prepared by solid state grinding of the mixture for about 5 min in a 
mortar using pestle without any solvent. These physical mixtures were analysed on DSC.  160 
The mixture of curcumin and cinnamic acid, at a molar ratio that shows formation of a 
co-crystal (as obtained from the binary phase diagram) was completely dissolved in the 
solvents such as acetone, ethanol, methanol and acetonitrile. The solvent was then allowed to 
evaporate slowly and completely at 30 
o
C to form crystals. The solid product so obtained was 
analysed by DSC, p-XRD and SEM. Fourier Transform Infra-Red spectra (FTIR) of the 165 
samples, as KBr pellets, were recorded on a Bruker-VERTEX 80V instrument, in absorbance 
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mode with 128 scans with resolution of 1 cm
-1
. All the above experimental runs were 
performed in duplicates.  
Results and Discussion 
Polymorphic studies of Curcumin by anti-solvent method  170 
Solubility of curcumin in acetone is stated to be greater than 2 (w/w %) 
39
 but it is less 
than 5 µM in water at the ambient temperature of 30
o
C
 40, 41
. Therefore, acetone was chosen 
as good solvent while water acts as an anti-solvent. However, no data on solubility of 
curcumin in the water + acetone mixtures at different weight ratios are available. But it is 
clear that pure water shows an extremely low solubility of curcumin and thus the entire 175 
amount of curcumin can be precipitated by addition of water as anti-solvent to solutions of 
curcumin in acetone. 
The DSC plots in Figure 1 (a) and (b) show the effect of solvent-to-anti-solvent ratio on 
curcumin precipitation; where, the volume of the solvent is increased keeping the volume of 
the anti-solvent constant and when volume of the anti-solvent is increased keeping the 180 
volume of the solvent constant, respectively. In Figure 1 (a), an endothermic peak at 174 °C 
corresponds to the melting point of a polymorph of curcumin (Form 2)
22
, which is seen to be 
followed by re-crystallization of this polymorph at 179 °C followed by melting, giving the 
second endotherm at around 184°C (Form 1).
 
The low temperature endotherm followed by 
melting and re-crystallization is the characteristic of a metastable polymorph 
17
; here, the 185 
Form 2 of curcumin. Each plot with varying solvent-to-anti-solvent ratio shows similar 
characteristics confirming the formation of the polymorph over the entire range of solvent 
composition.  
Figure 2 shows p-XRD spectra of curcumin obtained by varying the solvent-to-anti-
solvent ratio. The Form 2 of curcumin has a characteristic peak at 2 of 14° while the 190 
absence of this peak at 2 of 14° and occurrence of additional smaller peaks at 2 of 26°and 
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27° show the presence of Form 1 of curcumin.
 22
 Although the polymorphic Form 2 is 
formed at various solvent to anti-solvent ratio, the p-XRD peaks show a significant loss in the 
crystallinity than the pure curcumin in Form 1. 
For the solvent ratios of 3:10 and 5:10, however, the p-XRD spectra show a sharp peak 195 
at 2 of 14° with the absence of the peaks at 26°and 27°, indicating precipitation of pure 
Form 2 of curcumin. The increase in the solvent-to-anti-solvent ratio leads to higher 
solubility of curcumin Form 1, precipitating Form 2 alone. Form 2 is more likely to 
precipitate being unstable than Form 1.
22
 
From the DSC and p-XRD results for varying solvent: anti-solvent ratios (Figures 1 and 200 
2), solvent-to-anti-solvent ratio of 3:10 showed the presence of pure Form 2 of curcumin.  
Hence, for varying pH conditions of anti-solvent, this ratio was selected. The DSC and p-
XRD analyses were performed on the solids obtained by the varying pH of the anti-solvent in 
the acidic range.  
The DSC plots in Figure 3 (a) indicate that at lower pH values ranging between 1 and 3, 205 
the metastable Form 2 polymorph is still formed, while at the pH of the anti-solvent, higher 
than 3, this Form 2 of curcumin is not seen at all. The reason can be due to the higher 
stability of curcumin at lower pH conditions.
43 
This results in the precipitation of both the 
forms of curcumin i.e. Form 1 and Form 2 together. At pH higher than 3, Form 1, which has 
a lower solubility; precipitates without Form 2.
22 
There is a possibility of phase 210 
transformation of Form 2 to Form 1 at pH above 3, leading to the precipitation of Form 1 
alone.
44
 
The p-XRD spectra in Figure 3 (b) are for polymorphs of curcumin precipitated by 
varying pH of the anti-solvent at 3:10 solvent-to-anti-solvent ratio. Similar to DSC, it 
indicates the presence of pure Form 1 of curcumin at pH conditions above 3; while at a pH 215 
lower than 3, mixture of both the forms, Form 1 and Form 2 of curcumin precipitate. Thus, in 
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a range of varying the solvent-to-anti-solvent ratio and the pH of the anti-solvent lower than 
3, the metastable Form 2 of curcumin can be formed easily. 
 The SEM images of the curcumin polymorphs suggest a wide variation in 
morphology with varying the solvent-to-anti-solvent ratio and the pH of the system. Figure 4 220 
(a-f) are the SEM images of the polymorphs for increasing solvent-to-anti-solvent ratio from 
1:10 to 1:2. The crystals agglomerate to form bigger clusters as seen for solvent-to-anti-
solvent ratio of 1:10 in Figure 4 (b). At a low solvent-anti-solvent ratio, the supersaturation 
increases drastically due to decrease in the solubility of curcumin, resulting into precipitation 
of a large number of smaller spherical aggregates. (One such aggregate is shown in Figure 4 225 
(b)) With increase in solvent-to-anti-solvent ratio to 2:10 (Figure 4(c)), the slight decrease in 
the supersaturation leads to precipitation of particles in a non-spherical agglomerate. The 
solubilization and precipitation compete with increasing the solvent content of the solutions. 
The spherical aggregate structure of curcumin crystals at lower solvent-to-anti-solvent ratio, 
changes to fine needle- like crystals at 3:10 solvent to anti-solvent ratio. At this ratio, the 230 
crystals are fiber like, which are loosely but regularly connected to form a mesh like structure 
(Figure 4 (d)). The increase in acetone content in the mixed solvents lowers degree of 
supersaturation and favors more solubilization of curcumin, resulting in the slow precipitation 
of the crystals, consequently maintaining supersaturation and hence  affecting the growth 
rates of the crystals. At 4:10 solvent-to-anti-solvent ratio, an excess of solvent increases the 235 
solubility of curcumin, that makes curcumin difficult to precipitate or growth of the already 
precipitated solids. The fibers are no longer dominant and the morphology turns to smaller 
and finer particles (Figure 4 (e)). This suggests that a polymorph exhibits a nano-mesh like 
structure only at a particular solvent-to-antisolvent ratio of 3:10 and the structure transforms 
to agglomerates and fine crystals both below and above this ratio.  240 
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The SEM images of changing morphologies of curcumin crystals with increase in 
antisolvent content, in the solution are shown in Figure 4 (f- i). Addition of water initially 
increases supersaturation; favoring precipitation of curcumin particles in agglomerate form 
with plate like morphologies as in case of 1:2 and 1:4 solvent-to-anti-solvent ratios. (Figure 4 
h, g) For the cases of 1:6 and 1:8 ratio i.e. with further increase in the anti-solvent content, the 245 
supersaturation increases significantly resulting in lower solubility of curcumin and hence 
favoring rapid precipitation of a larger number of smaller crystals leading to formation of an 
aggregate with a random morphology. (Figure 4 (h, i)) 
For the 3:10 solvent-to-antisolvent ratio, the pH of 1.5 of water shows two different 
morphologies, plate like and aggregates, while that for pH 2.3, it changed to amorphous 250 
aggregates (Figures 5 a, b). These structures suggest that at pH 1.5, two different polymorphs 
are present together, while increase in pH tends to precipitation of amorphous solid as also 
confirmed by p-XRD peaks as seen in Figure 3b. 
The experiments in duplication were also done, where all the samples which were 
analysed for DSC and p-XRD showed peaks in the similar range and the SEM showed a 255 
morphological difference corresponding to + 0.5 µm. 
Eutectics and Co-crystals of Curcumin - cinnamic acid: Binary phase diagram studies  
Few reports are available on formation of co-crystal and eutectics and their structural 
inter-relationships based on the phase solubility diagrams.
47,48 
To understand the region of co-
crystal formation, the binary phase diagram for the system of curcumin and cinnamic acid is 260 
developed further. The Differential Scanning Calorimetry (DSC) plots for varying mole 
fraction of curcumin in the mixture are shown in Figure 6. The phase diagram was plotted by 
plotting solidus (onset temperature for the first peak) and liquidus (peak temperature of the 
second peak) temperatures from all the DSC curves. (Figure 7) This gives an idea of 
curcumin mole fraction at which the co-crystal forms and the temperature till which it will be 265 
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stable. It was observed that the systems with the curcumin mole fraction of 0.15 and 0.33 
form the eutectics, E1 and E2, respectively, while, the system with curcumin mole fraction of 
0.3, forms a co-crystal.  
The mixture with the curcumin mole fraction of 0.3 was then further dissolved 
completely in various solvents such as acetone, ethanol, methanol and acetonitrile to obtain 270 
single crystals. But the single crystals which are suitable for the single crystal XRD analysis 
were not obtained from any of the solvent systems. Out of all the systems, crystallization 
carried out by evaporative crystallization from acetone followed by complete drying at 30 °C 
resulted in co-crystals and both the eutectics. The powder thus obtained was analysed further  
by DSC, p-XRD, FTIR and SEM. 275 
Figure 8 (a) shows comparison of the endothermal peaks for curcumin-cinnamic acid 
systems with 0.15, 0.3 and 0.33 mole fractions of curcumin in the mixtures, obtained after re-
crystallization in acetone. In the mixture of curcumin and cinnamic acid, containing 0.15 
mole fraction of the curcumin, there is only one endothermic peak at around 129°C 
suggesting the formation of an eutectic. For 0.3 mole fraction of curcumin in the mixture, an 280 
endothermal peak onset at 112°C and another peak is seen at 123 °C. This peak corresponds 
to the formation of a co-crystal as further evidenced by additional crystalline structure 
reflected in the p-XRD studies. For 0.33 mole fraction of curcumin in the mixtures with 
cinnamic acid, the first endothermic peak appears at 127°C which corresponds to the eutectic 
melting, which is very near to the eutectic melting of 129°C, as observed for the 0.15 mole 285 
fraction of curcumin in the mixture. It is followed by the second endothermic peak at 141°C, 
which is ascribed to the melting of the curcumin along with its co-crystal.
42
   
The p-XRD (Figure 8 (b)) suggests that, the pattern for the mixture containing 
curcumin mole fraction of 0.15 remains more or less similar to those of the parent 
compounds. For the  mixture having curcumin mole fraction of 0.33 forming eutectic E2,  the 290 
13 
 
p-XRD shows new and major characteristic peaks at 2θ of 11.11°, 12.15°, 14.47°, 15.69° and 
23.55°. Therefore, by analyzing the results of DSC and p-XRD together, one can suggest that 
the mixture of curcumin and cinnamic acid with 0.15 mole fraction of curcumin forms an 
eutectic E1, at 0.3 mole fraction of curcumin it forms a co-crystal and at 0.33 mole fraction of 
curcumin, the mixture forms another eutectic E2 along with the co-crystal.  295 
The experimental values of enthalpy (ΔHexperimental) were obtained from the DSC 
software itself. The enthalpy of fusion values were calculated using the mixture law
41
, as 
given by Eq. (1),  
ΔHcalc = x1 ΔH1 + x2 ΔH2                                         Eq. (1) 
 300 
where, ΔHcalc is the total enthalpy of fusion for a system comprising of the components 1 and 
2,  x1  and x2  are the respective mole fractions of the components present in the system with 
the individual enthalpies of fusion values (for pure components curcumin and cinnamic acid 
obtained from the DSC graphs) given by ΔH1 and ΔH2. The values obtained thus are given in 
Table 1. The experimentally determined values are lower than the calculated values for the 305 
eutectics as well as for co-crystals, indicating the presence of interaction between curcumin 
and cinnamic acid. Also, the enthalpy values of curcumin and cinnamic acid individually, are 
higher than those of the eutectics E1, E2 and co-crystal. This suggests stronger intra-molecular 
interactions within pure components molecules than the molecular interactions present in the 
eutectic or the co-crystal.
45 310 
The electrostatic charge distribution of individual molecules of curcumin and cinnamic 
acid (Figure 9 (a) and (c)) was obtained by Gaussian-09 software, using density functional 
theory (DFT) calculations with B3LYP functional and 6-311++G (d, p) basis set without any 
constraints.
45
 Also, the crystal packing structures of the individual molecules of curcumin and 
cinnamic acid (Figure 9 (b, d)) were obtained by Mercury software(version 3.10) 
46
, to study 315 
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possible intermolecular and intramolecular hydrogen bonding combinations. Out of the three 
hydroxyl groups in curcumin, the phenolic hydroxyl groups with the oxygen atom having 
electrostatic charges (-0.491 and -0.482) are more susceptible to hydrogen bonding than the 
oxygen atom present in the -enol group which has an electrostatic charge of -0.411. (Figure 9 
(a)) While the cinnamic acid shows no intramolecular H-bonding, the acidic –OH group 320 
functions as both, H-bond donor and acceptor. (Figure 9 (d)) These figures show the 
possibility of formation of hydrogen bond between the carbonyl =O (with electrostatic charge 
of -0.389) of cinnamic acid with the phenolic –OH of the curcumin to form a co-crystal.  
In the FTIR spectra (Figure S1) of eutectics and co-crystal of curcumin and cinnamic 
acid with individual pure components, at 3510 cm-1 in curcumin, characteristic symmetric 325 
stretching peak of –OH shows a shift to 3517 cm-1 for the 0.3 curcumin: cinnamic acid co-
crystal. While that for the eutecics E1 and E2  the same peaks are at 3513 cm
-1 and 3519 cm-1 
respectively. This increased frequency suggests that the –OH group of curcumin is involved 
in H-bond formation with carbonyl =O of cinnamic acid. Disappearance of the characteristic 
broad peak of carboxylic –OH stretching at 3000 cm-1 in cinnamic acid and smaller and 330 
sharper peaks appearing in the eutectics and the co-crystal around 3069 cm-1 suggests the 
involvement of the carboxylic acid’s –OH group in H-bond formation. However, the carbonyl 
stretching frequency which occurs at around 1685 cm-1 cinnamic acid, shows a shift to lower 
frequency at around 1675 cm-1 indicating conjugation of this C=O group, probably due to the 
intermolecular H-bonding. C–O–H bending frequencies, which occurs at 1429 cm-1  for 335 
curcumin shows a slight shift to 1426 cm
-1 
and 1424 cm
-1 
for a co-crystal and eutectic E1. 
Table 2 lists out the various major peaks from the FTIR spectra.  
From the spectral changes observed in FTIR studies (Table 2) and the optimised crystal 
structures with the electrostatic charges on the indivudual atom and also the packing 
15 
 
structures of these individual molecules (Figure 9 (a-d)), probable interaction between these 340 
two molecules in their co-crystal was predicted as shown in Figure 9 (e). The H-bonding 
occurs between the C=O group of cinnamic acid with the –OH group of curcumin in an axial 
direction, with the phenolic groups of curcumin and cinnamic acid are showing a slight shift 
in the plane beacuse of the π- π stacking interactions.    
Figure 10 (a-e) shows the SEM images of curcumin, cinnamic acid, 0.3 curcumin: 345 
cinnamic acid co-crystal and the eutectics E1 and E2. While pure curcumin seems to have 
random and variant sizes of the crystals, having different geometries; cinnamic acid has flat 
plate like structures. The co-crystals can be seen to be of a distorted oval morphology, with 
slightly porous nature (Figure 10 (d)) as compared to that of parent crystals which are 
comparatively non-porous. Improved porosity could mean higher surface area and hence 350 
better solubility rate of the co-crystal.
49
 Eutectics E1 and E2 both have varied morphology 
ranging from small powder like to bigger crystals (Figure 10 (c, e)). These studies indicate 
that co-crystal of curcumin with cinnamic acid at the mole fraction of 0.3 of curcumin, i.e. in 
almost 1:2 molar ratios may lead to better solubilization rate than curcumin alone. Further 
studies, however, need to be performed to obtain single crystals of this co-crystal, which will 355 
lead to dissolution studies necessary for its possible utilization in the field of pharmaceuticals. 
Conclusion 
Polymorph of curcumin, i.e. Form 2 was successfully prepared by an anti-solvent 
precipitation technique over a wide range of solvent: anti-solvent ratios and also under 
varying pH conditions. The solvent-to-anti-solvent ratio plays an important role in deciding 360 
the final morphology of the polymorph and the 3:10 solvent-to-anti-solvent ratio resulted in 
nano-precipitation of curcumin in a regular wire mesh like structure.  
For the binary system of curcumin and cinnamic acid, the phase diagram studies 
successfully showed the presence of eutectics E1 and E2 at the ratios of 0.15 and 0.33 of 
16 
 
curcumin mole fraction and the presence of a co-crystal at the curcumin mole fraction of 0.3. 365 
The analytical methods prove the formation of the cocrystal. With the help of electrostatic 
charges present on the optimized atoms along with the FTIR spectra, the possibility of 
hydrogen bond formation between curcumin and cinnamic acid in their co-crystal is 
presented. This co-crystal may have a possible application in the field of medicines because 
of the anti-oxidant and anti-cancer properties of cinnamic acid in addition to those of 370 
curcumin.   
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Figures 
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Figure 1 DSC showing effect of (a) increase in good solvent keeping volume of anti-
solvent constant (b) increase in anti-solvent keeping volume of good solvent constant 545 
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Figure 2 p-XRD showing the comparison plot of varying ratios of solvent: anti-
solvent 550 
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(a) 
 
 
(b) 565 
 
Figure 3 (a) DSC plot (b) p-XRD plot for 3:10 solvent to anti-solvent ratio with 
varying pH of anti-solvent 
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 570 
Figure 4 SEM images of (a) Curcumin and (b) the polymorphs of curcumin 
precipitated by anti-solvent precipitation method with acetone: water ratio as 1:10 
(c) 2:10 (d) 3:10 (e) 4:10 (f) 5:10 (g) 1:4 (h) 1:6 (i) 1:8  
 
 575 
 
Figure 5 SEM images of the polymorphs of curcumin precipitated by anti-solvent 
precipitation method with acetone: water ratio as 3:10 with (a) 1.5 pH of water  
(b) 2.3 pH of water 
 580 
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Figure 6 DSC for varying mole fractions of curcumin in various physical mixtures 
of curcumin and cinnamic acid 
 585 
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Figure 7 Binary phase diagram of curcumin-cinnamic acid system showing the 
solidus (squares) and the liquidus (diamonds) temperatures.  
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(a) 
 600 
(b) 
Figure 8 (a) DSC results of curcumin-cinnamic acid system showing 1:3 co-crystal and 
1:2 eutectic (b) p-XRD for the co-crystal system of curcumin-cinnamic acid 
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(c) 620 
 
(d) 
 
(e) 
Figure 9 Optimized chemical structures and crystal packing structures of a unit 625 
cell of (a, b) curcumin (c, d) cinnamic acid (e) possible interactions occurring in 
the co-crystal of curcumin and cinnamic acid  
 
Light blue: intramolecular hydrogen bonding  
Red: available sites for intermolecular hydrogen bonding  630 
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Figure 10 SEM images of (a) Curcumin (b) Cinnamic acid (c) 0.15 curcumin: cinnamic 
acid eutectic (d) 0.3 curcumin: cinnamic acid co-crystal (e) 0.33 curcumin: cinnamic 
acid eutectic 635 
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Figure S1 FTIR peaks for Curcumcin, cinnamic acid and there eutectics and co-crystal 
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